# Ferroptosis in Parkinson’s disease: a review of molecular mechanisms and emerging therapeutic strategies

**Authors:** Lingling Wang, Yue Zhang, Lei Guo

PMC · DOI: 10.3389/fnins.2026.1780573 · Frontiers in Neuroscience · 2026-02-20

## TL;DR

This review explores how ferroptosis, a type of cell death, contributes to Parkinson’s disease and highlights new treatment strategies targeting this process.

## Contribution

The paper introduces the synergistic relationship between α-synuclein aggregation and ferroptosis in Parkinson’s disease.

## Key findings

- α-synuclein aggregation directly induces ferroptosis and disrupts iron homeostasis.
- Iron accumulation accelerates α-synuclein fibrillation and oxidative stress, creating a harmful cycle.
- Glia cells amplify neurodegeneration by promoting inflammation and iron metabolism dysregulation.

## Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic (DA) neurons in the substantia nigra and the presence of Lewy bodies containing aggregated α-synuclein (α-syn). While these pathological hallmarks are well-established, the mechanisms underlying neuronal death remain incompletely understood. Emerging evidence highlights ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, as a critical pathway in PD pathogenesis. This review synthesizes recent advances elucidating the synergistic interplay between α-syn aggregation and ferroptosis. We detail how α-syn aggregation not only directly induces ferroptosis but also disrupts iron homeostasis, while iron accumulation in turn accelerates α-syn fibrillation and oxidative stress, forming a vicious cycle that propagates neurodegeneration. Furthermore, we explore the amplifying role of glial cells—microglia and astrocytes—in this process through the promotion of neuroinflammation, oxidative damage, and dysregulation of iron metabolism. Finally, we discuss promising therapeutic strategies targeting this α-syn-ferroptosis axis, including α-syn aggregation inhibitors, iron chelators, and glia-modulating agents, highlighting their potential as disease-modifying interventions. Together, these insights underscore ferroptosis as a central mechanism in PD and offer new avenues for developing targeted therapies.

## Linked entities

- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Genes:** COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, FOXD3 (forkhead box D3) [NCBI Gene 27022] {aka AIS1, Genesis, HFH2, VAMAS2}, ATP5PF (ATP synthase peripheral stalk subunit F6) [NCBI Gene 522] {aka ATP5, ATP5A, ATP5J, ATPM, CF6, F6}, PLP1 (proteolipid protein 1) [NCBI Gene 5354] {aka GPM6C, HLD1, MMPL, PLP, PLP/DM20, PMD}, Cth (cystathionine gamma lyase) [NCBI Gene 107869] {aka 0610010I13Rik, CGL, CSE, Cys3}, ABCA1 (ATP binding cassette subfamily A member 1) [NCBI Gene 19] {aka ABC-1, ABC1, CERP, HDLCQTL13, HDLDT1, HPALP1}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, PINK1 (PTEN induced kinase 1) [NCBI Gene 65018] {aka BRPK, PARK6}, TH (tyrosine hydroxylase) [NCBI Gene 7054] {aka DYT14, DYT5b, TYH}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, PVALB (parvalbumin) [NCBI Gene 5816] {aka D22S749}, Nfe2l2 (nuclear factor, erythroid derived 2, like 2) [NCBI Gene 18024] {aka Nrf2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CYBB (cytochrome b-245 beta chain) [NCBI Gene 1536] {aka AMCBX2, CGD, CGDX, GP91-1, GP91-PHOX, GP91PHOX}, SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657] {aka CCBR1, xCT}, slc7a11 (solute carrier family 7 member 11) [NCBI Gene 100151597], NOX4 (NADPH oxidase 4) [NCBI Gene 50507] {aka KOX, KOX-1, RENOX}, Fgf1 (fibroblast growth factor 1) [NCBI Gene 14164] {aka Dffrx, Fam, Fgf-1, Fgf2b, Fgfa}, TFR2 (transferrin receptor 2) [NCBI Gene 7036] {aka HFE3, TFRC2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, GSR (glutathione-disulfide reductase) [NCBI Gene 2936] {aka CNSHA10, GR, GSRD, HEL-75, HEL-S-122m}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, PRKN (parkin RBR E3 ubiquitin protein ligase) [NCBI Gene 5071] {aka AR-JP, LPRS2, PARK2, PDJ}, Cybb (cytochrome b-245, beta polypeptide) [NCBI Gene 13058] {aka CGD91-phox, Cgd, Cyd, Nox2, gp91-1, gp91phox}, CTH (cystathionine gamma-lyase) [NCBI Gene 1491] {aka CGL, CSE}, IREB2 (iron responsive element binding protein 2) [NCBI Gene 3658] {aka ACO3, IRE-BP 2, IRE-BP2, IRP2, IRP2AD, NDCAMA}, FTH1 (ferritin heavy chain 1) [NCBI Gene 2495] {aka FHC, FTH, FTHL6, HFE5, NBIA9, PIG15}, ATHS (atherosclerosis susceptibility (lipoprotein associated)) [NCBI Gene 470] {aka ALP}, got1 (glutamic-oxaloacetic transaminase 1, soluble) [NCBI Gene 406330] {aka wu:fj63b09, zgc:55996}, NCOA4 (nuclear receptor coactivator 4) [NCBI Gene 8031] {aka ARA70, ELE1, PTC3, RFG}, GCH1 (GTP cyclohydrolase 1) [NCBI Gene 2643] {aka DYT14, DYT5, DYT5a, GCH, GTP-CH-1, GTPCH1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, acsl4a (acyl-CoA synthetase long chain family member 4a) [NCBI Gene 393622] {aka acsl4, zgc:66186}, PARK7 (Parkinsonism associated deglycase) [NCBI Gene 11315] {aka DJ-1, DJ1, GATD2, HEL-S-67p}, Snca (synuclein, alpha) [NCBI Gene 20617] {aka NACP, alpha-Syn, alphaSYN}, MLRL (Myeloid leukemia-related gene (myeloid tumor suppressor)) [NCBI Gene 8201] {aka MLRG, MTS}, AHCYL1 (adenosylhomocysteinase like 1) [NCBI Gene 10768] {aka DCAL, IRBIT, PPP1R78, PRO0233, XPVKONA}, LRP1 (LDL receptor related protein 1) [NCBI Gene 4035] {aka A2MR, APOER, APR, CD91, DDH3, IGFBP-3R}, APOD (apolipoprotein D) [NCBI Gene 347], SLC40A1 (solute carrier family 40 member 1) [NCBI Gene 30061] {aka FPN, FPN1, HFE4, IREG1, MST079, MSTP079}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, LINC01194 (long intergenic non-protein coding RNA 1194) [NCBI Gene 404663] {aka CT49, TAG}, sirt1 (sirtuin 1) [NCBI Gene 797132] {aka im:7148963}, Alox12 (arachidonate 12-lipoxygenase) [NCBI Gene 11684] {aka 9930022G08Rik, Alox12p, P-12LO}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, TNFRSF11B (TNF receptor superfamily member 11b) [NCBI Gene 4982] {aka OCIF, OPG, PDB5, TR1}, CP (ceruloplasmin) [NCBI Gene 1356] {aka AB073614, CP-2}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, MTNR1A (melatonin receptor 1A) [NCBI Gene 4543] {aka MEL-1A-R, MT1}, GCLC (glutamate-cysteine ligase catalytic subunit) [NCBI Gene 2729] {aka CNSHA7, GCL, GCS, GLCL, GLCLC}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Slc7a11 (solute carrier family 7 (cationic amino acid transporter, y+ system), member 11) [NCBI Gene 26570] {aka 9930009M05Rik, sut, xCT}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, park7 (parkinson protein 7) [NCBI Gene 449674] {aka dj1, zgc:103725}, RAB8A (RAB8A, member RAS oncogene family) [NCBI Gene 4218] {aka MEL, RAB8}, MPO (myeloperoxidase) [NCBI Gene 4353], CLU (clusterin) [NCBI Gene 1191] {aka AAG4, APO-J, APOJ, CLI, CLU1, CLU2}, nfe2l2a (nfe2 like bZIP transcription factor 2a) [NCBI Gene 360149] {aka Nrf2, nfe2l2, wu:fc15g09, wu:fj67e03}
- **Diseases:** cancer (MESH:D009369), AD (MESH:D000544), CNMT (MESH:C564683), neurotoxic (MESH:D020258), synucleinopathies (MESH:D000080874), Central Nervous System (MESH:D002493), DLB (MESH:D020961), neuroinflammation (MESH:D000090862), brain trauma (MESH:D000070642), iron overload (MESH:D019190), LB disease (MESH:D004194), neurodegeneration (MESH:D019636), gastrointestinal symptoms (MESH:D012817), inflammation (MESH:D007249), PD (MESH:D010300), mitochondrial damage (MESH:D028361), motor deficits (MESH:D009461), metabolic dysfunction (MESH:D008659), iron (MESH:D000090463), damage (MESH:D020263), complex (MESH:D048090), MSA (MESH:D019578), contralateral rotation (MESH:D009759), immune disorders (MESH:D007154), retinal degeneration (MESH:D012162), EVNs (MESH:C535509), cytotoxicity (MESH:D064420), PQS (MESH:D011552), resting tremor (MESH:D014202), bradykinesia (MESH:D018476), demyelination (MESH:D003711), rigidity (MESH:D009127), ferroptosis,""lipid (MESH:D011017), necrosis (MESH:D009336), PE (MESH:D000092202), immune dysregulation (OMIM:614878), fibrillation (MESH:D014693), motor dysfunction (MESH:D000068079), DA (MESH:D009422), cognitive deficits (MESH:D003072), IPMDS (MESH:D009069), depressive (MESH:D003866), DA neuron loss (MESH:D009410), neurotoxic cytokines (MESH:D000080424), motor syndrome of parkinsonism (MESH:D010302)
- **Chemicals:** salidroside (MESH:C009172), Que (MESH:D011794), ether-PL (MESH:D010742), DFP (MESH:D000077543), rapamycin (MESH:D020123), lipid hydroperoxides (MESH:D008054), CoQ10 (MESH:C024989), Triacylglycerol (MESH:D014280), acteoside (MESH:C058956), CPT (MESH:C000708228), methionine (MESH:D008715), Z-ligustilide (MESH:C027820), DT (MESH:C000713095), 4-Hydroxynonenal (MESH:C027576), glutamate (MESH:D018698), isoprostanes (MESH:D028421), rotigotine (MESH:C047508), liproxstatin-1 (MESH:C000595890), 4-oxo-2-nonenal (MESH:C403894), hydroxyl radicals (MESH:D017665), aldehydes (MESH:D000447), PQS (MESH:C407944), S-adenosylhomocysteine (MESH:D012435), cholesterol (MESH:D002784), NO (MESH:D009569), 6-Hydroxydopamine (MESH:D016627), phospholipid (MESH:D010743), acetyl-CoA (MESH:D000105), Iron (MESH:D007501), NADPH (MESH:D009249), CEF (MESH:D002443), Dex (MESH:D064730), 8-OH-DPAT (MESH:D017371), BH4 (MESH:C003402), homocysteine (MESH:D006710), Se (MESH:D012643), MDA (MESH:D008315), GSSG (MESH:D019803), ZNS (MESH:D000078305), 1-Methyl-4-phenylpyridinium (MESH:D015655), curcumin (MESH:D003474), melatonin (MESH:D008550), levodopa (MESH:D007980), BJP-IVb (-), H2O2 (MESH:D006861), erastin (MESH:C477224), cystine (MESH:D003553), silica (MESH:D012822), fisetin (MESH:C017875), PUFAs (MESH:D005231), membrane lipids (MESH:D008563), alcohols (MESH:D000438), N-Acetylcysteine (MESH:D000111), Pyridoxal Phosphate (MESH:D011732), vitamin B6 (MESH:D025101), DA (MESH:D004298), calcium (MESH:D002118), ROS (MESH:D017382), LEV (MESH:D000077287), Ubiquinol (MESH:C003741)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Danio rerio (leopard danio, species) [taxon 7955]
- **Mutations:** A53T

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963228/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963228/full.md

## References

149 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963228/full.md

---
Source: https://tomesphere.com/paper/PMC12963228